GlaxoSmithKline plc (ADR) (GSK) EPS Estimated At $0.71

July 17, 2017 - By Marguerite Chambers

 GlaxoSmithKline plc (ADR) (GSK) EPS Estimated At $0.71

Analysts expect GlaxoSmithKline plc (ADR) (NYSE:GSK) to report $0.71 EPS on July, 26.They anticipate $0.01 EPS change or 1.43 % from last quarter’s $0.7 EPS. GSK’s profit would be $1.71B giving it 14.90 P/E if the $0.71 EPS is correct. After having $0.62 EPS previously, GlaxoSmithKline plc (ADR)’s analysts see 14.52 % EPS growth. It is down 4.26% since July 18, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Among 14 analysts covering GlaxoSmithKline (NYSE:GSK), 7 have Buy rating, 0 Sell and 7 Hold. Therefore 50% are positive. GlaxoSmithKline had 21 analyst reports since September 8, 2015 according to SRatingsIntel. The rating was initiated by Investec on Thursday, October 20 with “Buy”. As per Monday, October 12, the company rating was upgraded by JP Morgan. The firm earned “Neutral” rating on Friday, June 16 by J P Morgan Chase Co. On Wednesday, December 9 the stock rating was upgraded by Bank of America to “Buy”. The rating was upgraded by BNP Paribas on Wednesday, April 5 to “Neutral”. The firm earned “Neutral” rating on Wednesday, July 5 by Citigroup. The firm has “Neutral” rating by Bank of America given on Tuesday, September 8. The rating was maintained by Argus Research on Monday, December 7 with “Buy”. The stock has “Neutral” rating by Credit Suisse on Tuesday, October 20. The company was maintained on Wednesday, April 26 by JP Morgan.

GlaxoSmithKline plc is a global healthcare company. The company has market cap of $101.75 billion. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 47.2 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Another recent and important GlaxoSmithKline plc (ADR) (NYSE:GSK) news was published by Benzinga.com which published an article titled: “Healthcare Repeal Bad For GlaxoSmithKline, Other HIV Treatment Stocks” on July 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.